AP865A - Heterecyclic compounds useful as inhibitors of cysteine protease. - Google Patents
Heterecyclic compounds useful as inhibitors of cysteine protease. Download PDFInfo
- Publication number
- AP865A AP865A APAP/P/1997/001054A AP9701054A AP865A AP 865 A AP865 A AP 865A AP 9701054 A AP9701054 A AP 9701054A AP 865 A AP865 A AP 865A
- Authority
- AP
- ARIPO
- Prior art keywords
- scheme
- galkyl
- compounds
- formula
- cathepsin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2374296P | 1996-08-08 | 1996-08-08 | |
US4686797P | 1997-05-08 | 1997-05-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9701054A0 AP9701054A0 (en) | 1997-10-31 |
AP865A true AP865A (en) | 2000-08-17 |
Family
ID=26697548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1997/001054A AP865A (en) | 1996-08-08 | 1997-08-06 | Heterecyclic compounds useful as inhibitors of cysteine protease. |
Country Status (36)
Country | Link |
---|---|
EP (1) | EP0936912B1 (de) |
JP (1) | JP3948753B2 (de) |
KR (1) | KR100508045B1 (de) |
CN (1) | CN1171870C (de) |
AP (1) | AP865A (de) |
AR (1) | AR009020A1 (de) |
AT (1) | ATE259352T1 (de) |
AU (1) | AU721853B2 (de) |
BG (1) | BG64412B1 (de) |
BR (1) | BR9711044A (de) |
CA (1) | CA2262668C (de) |
CY (1) | CY2528B1 (de) |
CZ (1) | CZ297294B6 (de) |
DE (1) | DE69727586T2 (de) |
DK (1) | DK0936912T3 (de) |
DZ (1) | DZ2285A1 (de) |
EA (1) | EA001937B1 (de) |
ES (1) | ES2213831T3 (de) |
HK (1) | HK1022096A1 (de) |
HU (1) | HU222788B1 (de) |
ID (1) | ID18001A (de) |
IL (1) | IL128378A (de) |
MA (1) | MA24298A1 (de) |
MY (1) | MY116947A (de) |
NO (1) | NO317182B1 (de) |
NZ (1) | NZ333987A (de) |
OA (1) | OA10972A (de) |
PE (1) | PE99198A1 (de) |
PL (1) | PL191779B1 (de) |
PT (1) | PT936912E (de) |
RO (1) | RO120407B1 (de) |
SK (1) | SK285127B6 (de) |
TR (1) | TR199900249T2 (de) |
TW (1) | TW542825B (de) |
UY (2) | UY24660A1 (de) |
WO (1) | WO1998005336A1 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ132798A3 (cs) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
US6586466B2 (en) | 1995-10-30 | 2003-07-01 | Smithkline Beecham Corporation | Carbohydrazide-protease inhibitors |
US6566373B2 (en) * | 1997-05-06 | 2003-05-20 | Smithkline Beecham Corporation | Protease inhibitors |
US6369077B1 (en) * | 1997-05-08 | 2002-04-09 | Smithkline Beecham Corporation | Protease inhibitors |
BR9815200A (pt) | 1997-10-27 | 2001-10-16 | Agouron Pharma | Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina |
MA26618A1 (fr) * | 1998-04-09 | 2004-12-20 | Smithkline Beecham Corp | Composes et compositions pharmaceutiques pour le traitement du paludisme |
CN1253441C (zh) * | 1998-12-23 | 2006-04-26 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
AU2003261482B2 (en) * | 1998-12-23 | 2007-01-25 | Smithkline Beecham Corporation | Protease inhibitors |
EP1384713B1 (de) * | 1998-12-23 | 2008-10-15 | SmithKline Beecham Corporation | 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors |
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
CO5180541A1 (es) * | 1998-12-23 | 2002-07-30 | Smithkline Beechman Corp | Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros |
TW200404789A (en) | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
WO2001034599A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
EP1229912A4 (de) * | 1999-11-10 | 2003-05-07 | Smithkline Beecham Corp | Proteaseinhibitoren |
WO2001034157A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
US6583137B1 (en) | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
EP1351930A4 (de) * | 1999-11-10 | 2004-09-15 | Smithkline Beecham Corp | Protease inhibitoren |
WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
JP2003513924A (ja) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
AU1474601A (en) * | 1999-11-10 | 2001-06-06 | Smithkline Beecham Corporation | Protease inhibitors |
EP1229915A4 (de) * | 1999-11-10 | 2003-05-14 | Smithkline Beecham Corp | Proteasehemmer |
EP1229911A4 (de) * | 1999-11-10 | 2003-05-07 | Smithkline Beecham Corp | Proteaseinhibitoren |
CN1416346A (zh) | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
CO5280088A1 (es) * | 2000-04-18 | 2003-05-30 | Smithkline Beecham Corp | Inhibidores de proteasa |
SK17592002A3 (sk) * | 2000-06-14 | 2003-05-02 | Smithkline Beecham Corporation | 4-Amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty |
WO2002017924A1 (en) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Method of treatment |
US20040102431A1 (en) * | 2000-09-25 | 2004-05-27 | Christoph Boss | Substituted amino-aza-cycloalkanes useful against malaria |
US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
US7064123B1 (en) | 2000-12-22 | 2006-06-20 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
MXPA03006224A (es) | 2001-01-17 | 2004-10-15 | Amura Therapeutics Ltd | Inhibidores de cruzipaina y otras proteasas de cisteina. |
US7132449B2 (en) | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
IL156776A0 (en) | 2001-01-17 | 2004-02-08 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
HUP0303258A3 (en) | 2001-02-23 | 2004-06-28 | Merck & Co Inc | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them |
US6710061B2 (en) | 2001-03-09 | 2004-03-23 | Ortho-Mcneil Pharamceutical, Inc. | Aminopyrrolidine sulfonamides as serine protease inhibitors |
US6538017B2 (en) | 2001-03-09 | 2003-03-25 | Ortho-Mcneil Pharmaceutical, Inc. | Aminopyrrolidine sulfonamides as serine protease inhibitors |
CA2443108A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
WO2003024924A1 (en) | 2001-09-14 | 2003-03-27 | Aventis Pharmaceuticals Inc. | Novel compounds and compositions as cathepsin inhibitors |
HUP0401906A3 (en) | 2001-11-14 | 2008-07-28 | Aventis Pharma Inc | Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them |
EP1465862A1 (de) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl-ketoamiden derivate und ihre verwendung als cathepsin-k-inhibitoren |
KR100962972B1 (ko) | 2002-07-26 | 2010-06-09 | 주식회사유한양행 | 1-페닐피페리딘-3-온 유도체 및 그의 제조방법 |
US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
CN100368018C (zh) * | 2005-05-26 | 2008-02-13 | 福建医科大学 | 蛇毒半胱氨酸蛋白酶抑制剂抗肿瘤侵袭与转移作用及应用 |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2009087379A2 (en) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
KR20220115062A (ko) | 2021-02-09 | 2022-08-17 | (주)오스티오뉴로젠 | 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994471A (en) * | 1989-05-12 | 1991-02-19 | Boc, Inc. | N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds |
US5216168A (en) * | 1992-04-01 | 1993-06-01 | G. D. Searle & Co. | 2- and 3- amino and azido derivatives of 1,5-iminosugars |
US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057525A (en) * | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
US5206251A (en) * | 1992-04-01 | 1993-04-27 | G. D. Searle & Co. | 2- and 3- amino and azido derivatives of 1,5-iminosugars |
US5374623A (en) * | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
CA2111930A1 (en) * | 1992-12-25 | 1994-06-26 | Ryoichi Ando | Aminoketone derivatives |
US5585387A (en) * | 1994-10-07 | 1996-12-17 | Torcan Chemical Ltd. | Prepration of cisapride |
CZ132798A3 (cs) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
-
1997
- 1997-08-03 DZ DZ970135A patent/DZ2285A1/fr active
- 1997-08-05 MY MYPI97003566A patent/MY116947A/en unknown
- 1997-08-06 AP APAP/P/1997/001054A patent/AP865A/en active
- 1997-08-06 UY UY24660A patent/UY24660A1/es not_active IP Right Cessation
- 1997-08-07 DK DK97937146T patent/DK0936912T3/da active
- 1997-08-07 AT AT97937146T patent/ATE259352T1/de not_active IP Right Cessation
- 1997-08-07 TR TR1999/00249T patent/TR199900249T2/xx unknown
- 1997-08-07 CN CNB971985324A patent/CN1171870C/zh not_active Expired - Fee Related
- 1997-08-07 AR ARP970103593A patent/AR009020A1/es active IP Right Grant
- 1997-08-07 RO RO99-00137A patent/RO120407B1/ro unknown
- 1997-08-07 EP EP97937146A patent/EP0936912B1/de not_active Expired - Lifetime
- 1997-08-07 SK SK162-99A patent/SK285127B6/sk not_active IP Right Cessation
- 1997-08-07 ES ES97937146T patent/ES2213831T3/es not_active Expired - Lifetime
- 1997-08-07 PL PL331533A patent/PL191779B1/pl not_active IP Right Cessation
- 1997-08-07 BR BR9711044-2A patent/BR9711044A/pt not_active Application Discontinuation
- 1997-08-07 EA EA199900186A patent/EA001937B1/ru not_active IP Right Cessation
- 1997-08-07 DE DE69727586T patent/DE69727586T2/de not_active Expired - Fee Related
- 1997-08-07 MA MA24759A patent/MA24298A1/fr unknown
- 1997-08-07 PE PE1997000689A patent/PE99198A1/es not_active Application Discontinuation
- 1997-08-07 KR KR10-1999-7001027A patent/KR100508045B1/ko not_active IP Right Cessation
- 1997-08-07 JP JP50821398A patent/JP3948753B2/ja not_active Expired - Fee Related
- 1997-08-07 CA CA002262668A patent/CA2262668C/en not_active Expired - Fee Related
- 1997-08-07 PT PT97937146T patent/PT936912E/pt unknown
- 1997-08-07 HU HU9902409A patent/HU222788B1/hu not_active IP Right Cessation
- 1997-08-07 NZ NZ333987A patent/NZ333987A/xx unknown
- 1997-08-07 WO PCT/US1997/013875 patent/WO1998005336A1/en active IP Right Grant
- 1997-08-07 AU AU39726/97A patent/AU721853B2/en not_active Ceased
- 1997-08-07 ID IDP972743A patent/ID18001A/id unknown
- 1997-08-07 IL IL12837897A patent/IL128378A/xx not_active IP Right Cessation
- 1997-08-07 CZ CZ0036299A patent/CZ297294B6/cs not_active IP Right Cessation
- 1997-09-22 TW TW086111564A patent/TW542825B/zh not_active IP Right Cessation
-
1998
- 1998-01-29 UY UY24863A patent/UY24863A1/es not_active IP Right Cessation
-
1999
- 1999-02-03 BG BG103144A patent/BG64412B1/bg unknown
- 1999-02-05 NO NO19990548A patent/NO317182B1/no not_active IP Right Cessation
- 1999-02-08 OA OA9900026A patent/OA10972A/en unknown
-
2000
- 2000-02-23 HK HK00101085A patent/HK1022096A1/xx not_active IP Right Cessation
-
2005
- 2005-07-26 CY CY0500042A patent/CY2528B1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
US4994471A (en) * | 1989-05-12 | 1991-02-19 | Boc, Inc. | N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds |
US5216168A (en) * | 1992-04-01 | 1993-06-01 | G. D. Searle & Co. | 2- and 3- amino and azido derivatives of 1,5-iminosugars |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP865A (en) | Heterecyclic compounds useful as inhibitors of cysteine protease. | |
ES2259617T3 (es) | Compuestos heterociclicos y su aplicacion como medicamentos. | |
EP0277588B1 (de) | Prolinalderivate | |
KR950013849B1 (ko) | 프롤리날 유도체 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
FR2609716A1 (fr) | Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments | |
EP0991753A1 (de) | Proteaseinhibitoren | |
NZ337889A (en) | Cysteine Protease inhibitors of the Papain superfamily comprising cathepsin K protease inhibitors | |
CZ144798A3 (cs) | Nové makrocyklické sloučeniny jako metaloproteinázové inhibitory | |
JP2001501193A (ja) | システイン・プロテイナーゼ調節剤としての4―置換―3―(2―アミノ―2―シクロアルキルメチル)―アセトアミドアゼチジン―2―オン誘導体 | |
WO1998008802A1 (en) | Inhibitors of cysteine protease | |
EP0280956A1 (de) | Thiazolidin-Derivate | |
CA2332492A1 (en) | Protease inhibitors | |
CA2334652A1 (en) | Protease inhibitors | |
EP1173429A1 (de) | Proteaseinhibitoren | |
US6566373B2 (en) | Protease inhibitors | |
WO2001040263A1 (fr) | Derives de 1,3,4-oxadiazoline-2-one et medicaments contenant ces derives utiles comme ingredient actif | |
CA2348048A1 (en) | Method of producing peptidylaldehyde | |
EP1384713B1 (de) | 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors | |
US20020082426A1 (en) | Protease inhibitors | |
Clive et al. | Synthesis and in vitro activity of a non-epimerizable analog of the angiotensin-converting enzyme inhibitor A58365A | |
JPH05163221A (ja) | オキシ酸誘導体 | |
MXPA99010254A (en) | Protease inhibitors | |
CZ388799A3 (cs) | Inhibitory proteasy | |
EP1503991A1 (de) | Hexahydropyridazin-3-carbonsäurederivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung | |
CZ395399A3 (cs) | Inhibitory proteasy |